TargetBeta
IL12B
interleukin 12B · also CLMF, IL-12B, NKSF, CLMF2 · Immunoglobulin like domain containing
4 programs in company-led studies act on IL12B, from 4 companies: 0 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| guselkumabrule | Johnson & Johnson | phase 4 | 6019 running | IL23A | ChEMBL |
| risankizumabrule | AbbVie | phase 4 | 6816 running | IL23A | ChEMBL |
| mirikizumabrule | Eli Lilly | phase 4 | 367 running | IL23A | ChEMBL |
| PF-07261271 | Pfizer | phase 1 | 10 running | TNFSF15 | the company's pipeline |
Conditions their studies are in
- Colitis, Ulcerative, 3 programs
- Crohn Disease, 3 programs
- Psoriasis, 3 programs
- Arthritis, Juvenile, 2 programs
- Arthritis, Psoriatic, 2 programs
- Breast Feeding, 1 program
- Inflammatory Bowel Diseases, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 20, 2026guselkumab · Johnson & Johnson · phase 4 · NCT07788807
- Jan 2027risankizumab · AbbVie · phase 4 · NCT07466550
- Feb 2027mirikizumab · Eli Lilly · phase 4 · NCT07446101
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.